Bladder Cancer Coverage from Every Angle

The Hormone Ghrelin: Potential Prognostic Predictor in Muscle-Invasive Bladder Cancer?

By: Jenna Carter, PhD
Posted: Tuesday, June 1, 2021

Research has shown that the hormone ghrelin, known to regulate appetite and growth, may also regulate processes related to cancer. In a recent article published in Translational Andrology and Urology, researchers examined the impact of ghrelin levels on survival rates in patients treated with chemotherapy for muscle-invasive bladder cancer. Takuya Koie, MD, PhD, of Gifu University Graduate School of Medicine, Gifu, Japan, and colleagues found that ghrelin appeared to be significantly associated with progression-free survival in this patient population.

Clinical records for a total of 56 patients diagnosed with muscle-invasive bladder cancer were examined. Blood samples were collected from 27 patients before chemotherapy and after two completed cycles of chemotherapy. Serum acyl ghrelin and des-acyl ghrelin were measured using enzyme-linked immunosorbent assay kits, and statistical analyses were performed to assess the association between ghrelin levels and survival rates.

Overall findings revealed 3-year overall survival and progression-free survival rates of 82.9% and 68.3%, respectively. After chemotherapy, the 3-year progression-free survival rates were 77.5% in patients with acyl ghrelin levels of at least 1.34 pg/mL and 53% in those with levels less than 1.34 pg/mL (P = .038). They also found that the 3-year progression-free survival rate was 90.9% in patients with desacyl ghrelin levels less than 92.3 pg/mL and 43.3% in patients with levels of at least 92.3 pg/mL (P = .039).

According to Dr. Koie and colleagues, multivariate analyses revealed that serum acyl ghrelin levels were significantly associated with progression-free survival, suggesting it could be a useful prognostic predictor in patients with muscular-invasive bladder cancer. Future work will need to uncover the exact molecular mechanisms by which acyl ghrelin and des-acyl ghrelin modulate muscle-invasive bladder cancer.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.